A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Nave Persons With HIV-1 (INNOVATE Study)
Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-19
Target enrollment:
Participant gender:
Summary
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.